Dr Alo argues semaglutide's bigger story is heart protection, citing SELECT trial results showing fewer cardiovascular events in people without diabetes.
Recap by typeshit. Post by @dr.alo on Instagram.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Quartz says four in ten patients stop GLP-1 drugs like Ozempic, and looks at a newer injection designed around that problem.
The post says four in ten patients drop GLP-1 drugs within a year over side effects, and pharma is turning to amylin-based shots as the next step.
Loading…